Eyenovia Provides Development Update on Optejet User Filled Device (UFD)

Core Insights - Eyenovia, Inc. is advancing its Optejet UFD, a user-filled device designed for various topical ophthalmic liquids, targeting multiple billion-dollar markets [1][2] - The company has completed significant Verification & Validation studies to ensure the device meets customer requirements and is on track for a 510(k) submission by September [2] - The Optejet UFD aims to enhance user experience by allowing consumers to obtain twice as many uses from their current eyedrops [2] Company Overview - Eyenovia, Inc. specializes in ophthalmic technology, focusing on developing and commercializing advanced products using its proprietary Optejet platform [3] - The current commercial portfolio includes clobetasol propionate ophthalmic suspension for post-surgical pain and inflammation, and Mydcombi® for mydriasis [3] Product Development - The Optejet UFD has undergone extensive testing, including usability, dosing performance, and safety testing, demonstrating its capability to dispense ophthalmic solutions accurately and reliably [5][6] - Key components of the device have been tested over 30,000 times, confirming its durability and performance standards [5] Market Potential - The combination of the Optejet UFD with artificial tears or lens rewetting solutions is expected to significantly improve treatment options and outcomes for patients [2][3]